Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Carotid Artery Disease Clinical Trials

A listing of Carotid Artery Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to CEA plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to CAS plus intensive medical management. Intensive medical management ...

Phase N/A

CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to CEA plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to CAS plus intensive medical management. Intensive medical management ...

Phase N/A

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.

Phase N/A

Assessing Neurocognition After Cerebrovascular Intervention

Patients are being asked to partake in this study because the PI has decided on clinical grounds as outlined in the clinical trial, NASCET, (either asymptomatic 70% carotid stenosis or symptomatic >50% carotid stenosis) that CAS or CEA is indicated. The only aspect of the study that is research is ...

Phase N/A

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

The ROADSTER 2 Study is intended to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying experience with the transcarotid technique.

Phase N/A

Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS

Background: Injection of ultrasound contrast agents, in conjunction with contrast specific imaging techniques, is increasingly accepted in clinical use for diagnostic ultrasound imaging. As microbubbles contrast agents appear to be ideal pure intravascular tracers to enhance the vascular lumen and more important to assess the dynamic spatial and temporal heterogeneity ...

Phase N/A

Prognostic Value of Carotid CEUS in Acute Ischemic Stroke Patients

Contrast-enhanced ultrasound(CEUS) of carotid artery plaque is a novel method that enabled direct visualization of neovessels in the vulnerable plaque. Plaque enhancement with CEUS showed correlation with the histologic density of neovessels within the carotid plaque and the previous cardiovascular events. Vulnerable plaques with a high risk of thromboembolic complications ...

Phase N/A

Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control

Cerebrovascular accident (CVA) constitutes a major health public problem. This represents the second cardiovascular death cause. CVA is ischemic in 80% of cases. Atheroma of large arteries, mainly carotid, is involved in about 20% of cases. After several high grade studies (NASCET, ECST, ACAS, ACST), carotid surgery is based on ...

Phase N/A

Stroke and Cerebrovascular Diseases Registry

Stroke is the fifth cause of all-cause mortality in US http://www.cdc.gov/stroke/facts.htm Early identification and treatment not only prevent mortality but also morbidity. Recent advancement in the imaging and diagnostic technique and novel therapeutic modalities has dramatically helped to downgrade stroke from the list of top mortality index in the last ...

Phase N/A

PERIODONTITIS AND VASCULAR DYSFUNCTION

The investigators wish to assess whether intensive periodontal therapy will reduce the burden of chronic periodontal disease and will cause regression or prevent progression of atherosclerosis assessed by a surrogate endpoint (carotid intimamedia thickness) at 24 months compared to control periodontal therapy.

Phase N/A